CRISPR Therap

CRSP.US closed down 5.45% at $48.57, opening high and then falling after HCA Healthcare published a NEJM study showing its CRISPR therapy exa-cel met 12-month endpoints in children aged 5-11 with sickle cell disease and beta thalassemia. The intraday high of $50.78 was followed by a decline to $47.90, with the post-market session settling at $48.64. Despite the positive clinical readout, market concerns over revenue scale persisted as Q1 2026 revenue was only $1.458 million (up 68.55% YoY) but net loss stood at $122.9 million with a net profit margin of -8431% and EPS of -$1.28. The stock initially surged to $51.63 in pre-market before turning negative, breaking below the previous close of $51.37. The current price-to-book ratio is 2.64x with a market cap of $4.78 billion, while analysts' 12-month price target has been adjusted from $80.62 to $81.1, implying approximately 64% upside. However, the stock remains near the middle of its 52-week range with pipeline catalysts from CASGEVY and CAR-T programs expected in late 2026.

CRISPR Therapeutics experienced a sharp intraday decline of approximately 5% on Monday, trading at $50.665 as of 1:53 PM ET, down 5.03%, pressured by a weak pre-market session (low $52.25). The stock opened lower and steadily dropped to a session low of $50.665, continuing its recent pullback. Despite Q1 2026 revenue growth of 68.55% to $1.458 million and a narrower net loss of $122.9 million, the company remains loss-making with an EPS of -$1.28, offering little immediate support. Analyst price targets have been lowered from $80.62 to $81.1, implying 69% upside, yet near-term sentiment is dampened by technical weakness, with the stock trading well below its 52-week high. However, a post-market bounce to $54.00 and continued clinical progress for CASGEVY provide a contrasting tone for longer-term outlook.

CRISPR Therapeutics AG opened sharply lower during regular trading on ET at 09:30, with a price of $55.47, quickly dropping to an intraday low of $53.44 by 09:38, representing a decline of approximately 3.6% from the open and reversing gains made in pre-market trading, which had touched a high of $56.74. The stock fell below its 20-day moving average of $55.045 and is now trading near the 60-day moving average of $53.528, positioning it in the middle-to-lower range of its 52-week band ($44.12–$78.48), with a 31.86% decline from its 52-week high and a year-to-date loss of 0.55%. While Q1 2026 revenue expanded 68.55% year-over-year to $1.458 million, the net loss remained substantial at $122.9 million, with an EPS of -$1.28 that improved 19.11% from the prior year, though profitability remains elusive. Trading volume surged to over 127,000 shares in just nine bars, indicating heightened activity, yet the sharp sell-off may attract short-term bargain hunters given the proximity to the 60-day moving average.

CRSP.US 今日盘中单边下行，收跌 5.02% 报 56.22 美元，主因是市场对 HCA 医疗在《新英格兰医学杂志》发布的 exa-cel 在 5-11 岁儿童中 12 个月终点阳性数据反应平淡，反而在原有利好消化后出现获利了结。盘中从 60.43 美元（ET 09:55）高点持续回落至 56.29 美元（ET 15:22），回吐全部盘前涨幅。Q1 2026 营收同比增 68.55% 至 145.8 万美元，净亏损 1.229 亿美元同比收窄 9.61%，亏损幅度改善但整体仍处高额研发投入阶段。当前股价处 52 周低点 44.12 美元之上 27.43%，但距 52 周高点 78.48 美元仍跌 28.36%，且低于 MA20（54.84 美元）仅 2.5%，不过 MA60（53.58 美元）仍构成短期支撑，YTD 仍录得 4.56% 涨幅。

CRISPR Therapeutics staged a low-opening rally on July 8, closing at $59.28, down 2.45% from the prior close of $60.77, but with significant intraday volatility from a pre-market low of $58.25 to a high of $60.33, and a slight post-market rebound to $59.20. The move was driven by an HCA Healthcare-published NEJM study showing CASGEVY met 12-month endpoints in children aged 5-11 with sickle cell disease and beta thalassemia, though profit-taking after recent gains prevented a full recovery. The stock remains 24.5% below its 52-week high of $78.48 but has gained 10.3% year-to-date from $53.77 and sits above both the 20-day ($54.60) and 60-day ($53.56) moving averages, indicating near-term technical improvement. However, intraday dips below $58 underscore persistent tug-of-war among traders, with upcoming pipeline data catalysts likely to determine the next leg.